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Abstract
Purpose To analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based 
molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response 
to neoadjuvant chemotherapy (NACT), and overall survival (OS).
Methods Patients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast 
cancer subtypes: HR+/HER2− , HR+/HER2+ , HR−/HER2+ , and HR−/HER2− . Patient-, tumor- and treatment-related 
characteristics were compared. In case of NACT, pathologic complete response (pCR) was compared between subgroups. 
OS of the subtypes was compared using Kaplan–Meier curves and the log-rank test.
Results 1061 patients with stage III IBC were grouped into subtypes: HR+/HER2− (N = 453, 42.7%), HR−/HER2− (N = 258, 
24.3%), HR−/HER2+ (N = 180,17.0%), and HR+/HER2+ (N = 170,16.0%). In total, 679 patients (85.0%) received NACT. 
In HR−/HER2+ tumors, pCR rate was highest (43%, (p < 0.001). In case of pCR, an improved survival was observed for all 
subtypes, especially for HR+/HER2+ and HR−/HER2+ tumor subtypes. Trimodality therapy (NACT, surgery, radiotherapy) 
improved 5-year OS as opposed to patients not receiving this regimen: HR+/HER2− (74.9 vs. 46.1%), HR+/HER2+ (80.4 
vs. 52.6%), HR−/HER2+ (76.4 vs. 29.7%), HR−/HER2− (47.6 vs. 27.8%).
Conclusions In stage III IBC, breast cancer subtypes based on the HR and HER2 receptor are important prognostic factors 
of response to NACT and OS. Patients with HR−/HER2− IBC were less likely to achieve pCR and had the worst OS, irre-
spective of receiving most optimal treatment regimen to date (trimodality therapy).
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Introduction
Inflammatory breast cancer (IBC) is the most aggressive 
form of breast cancer, and is associated with a dismal 
prognosis compared to non-IBC in patients with and with-
out distant metastases [1, 2]. At presentation, almost 80% 
of IBC patients have lymph node involvement and nearly 
40% present with distant metastases [3], of which lungs, 
liver, brain, and skeleton are the most frequent sites [4].
In breast cancer, four subtypes have been identified 
based on the hormone receptors (HR) [estrogen recep-
tor (ER), progesterone receptor (PR)] and Human Epi-
dermal growth factor Receptor-2 (HER2) [5]. These 
subtypes include HR+/HER2− (luminal A), HR+/
HER2+ (luminal B), HR−/HER2− (triple negative), and 
HR−/HER2+ (HER2-enriched) [6].
In non-IBC, HER2-enriched and triple-negative tumors 
have increased breast cancer-specific mortality in compari-
son with the other subtypes [7, 8]. For IBC, a recent analy-
sis of the American National Cancer Database showed that 
HR-positive disease was not associated with an advanta-
geous prognosis, and HER2-enriched status was not cor-
related with unfavorable overall survival (OS). Triple-neg-
ative and HR+/HER2− subtypes both showed significantly 
worse survival compared to the other subgroups [9].
Current treatment of stage III IBC includes neoadjuvant 
chemotherapy (NACT), surgery, and adjuvant locoregional 
radiotherapy (trimodality therapy). Moreover, (neo)adju-
vant trastuzumab and (neo)adjuvant endocrine therapy are 
applied in patients with HER2-positive and/or HR-positive 
tumors, respectively. This has positively influenced the 
survival of IBC patients in recent years [3]. Sensitivity to 
NACT might be used as an indicator for survival, since 
pathologic complete response (pCR) is a predictor of 
favorable long-term outcome [10]. In non-IBC, the inci-
dence and prognostic impact of pCR varies among breast 
cancer subtypes [11]. HER2-enriched and triple-negative 
tumors are more likely to achieve pCR after neoadjuvant 
systemic therapies, which improves survival in these sub-
groups [12]. However, patients with residual disease have 
significantly worse survival if they have triple-negative 
breast cancer [11].
Due to the low incidence, and variety in case definition, 
data about IBC are scarce and diverse [13]. Furthermore, 
several population-based studies regarding IBC have pre-
sented contradictory results concerning the association 
of HR status and prognosis [9, 14]. These inconsistent 
results might be due to limited sample sizes in single-
center or small multicenter studies [15], comparison of 
populations treated in different eras before the availability 
of anti-HER2-targeted therapy [14], or the lack of infor-
mation on systemic therapy in general [9]. We examined 
the significance of HR/HER2-based subtypes in stage III 
IBC on clinicopathological characteristics, pCR, and OS 
in a nationwide patient cohort, selected from the Nether-
lands Cancer Registry (NCR), in which the TNM-based 
definition of IBC has not changed over time with available 
information on systemic and targeted therapy.
Materials and methods
Data source
The NCR is a nationwide population-based cancer regis-
try. All newly diagnosed malignancies in the Netherlands 
are recorded and notified through the nationwide Pathology 
Archive (PALGA), which collects all pathology reports of 
Dutch hospitals (N = 92). Trained NCR registrars directly 
collect patient-, tumor- and treatment-related characteristics 
from the patient’s medical records. The NCR collects cancer 
incidence data covering more than 95% of all cancer patients 
in the Netherlands [16]. Morphology and differentiation are 
graded according to the International Classification of Dis-
eases for Oncology [17]. Staging is performed according to 
the TNM classification [18, 19]. With respect to IBC, the 
TNM criteria have not changed over time. The municipal 
administration was used to verify the patient’s vital status 
and, if applicable, date of death through a yearly linkage. 
Follow-up has been completed until February 29, 2016. The 
privacy committee of the NCR has approved this study.
Patients and study variables
Patients, diagnosed from 2006 to 2015, with clinical 
T4dN0–3M0 breast cancer were identified, excluding 
patients with only a pathological T4d status without clini-
cal T4d status.
The year 2006 was selected as the start of the analysis 
since HER2 was not routinely collected prior to 2006. His-
tological type and HR/HER2 status were assessed in the 
primary tumor from a needle biopsy prior to any therapy. 
Patients were classified into four breast cancer subtypes, 
based on HR status and HER2 status: HR+ (ER+ and/
or PR+)/HER2− , HR+ (ER+ and/or PR+)/HER2+, 
HR− (ER− and PR−)/HER2+ (HER2-enriched), and 
HR− (ER− and PR−)/HER2− (triple negative). Patients 
were excluded when data on HR and/or HER2 receptor sta-
tus were missing.
According to Dutch guidelines, ER/PR status had been 
determined with immunohistochemistry (IHC). At least 10% 
positive tumor nuclei were considered as a positive result. 
In the Netherlands, HER2 status was considered positive 
with an immunohistochemical score of 3 + (at least 10% 
of tumor cells with strong complete membrane staining) 
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or amplification of the HER2 gene diagnosed with in situ 
hybridization (ISH) (in at least 10% of tumor cells show-
ing a ratio of HER2 probe to centromere chromosome 17 
probe of > 2.2 or with single probe HER2 test when mean > 6 
HER2 genes per tumor nucleus were detected) or with other 
amplification-based techniques, such as multiplex ligation-
dependent probe amplification (MLPA). In case of an 
immunohistochemical score of 2 + (at least 10% of tumor 
cells with slight to moderate complete membrane staining, 
considered as an equivocal result), ISH or MLPA was per-
formed. If in this case HER2 was found to be amplified, 
HER2 was considered positive. HER2 status was considered 
negative with an immunohistochemical score of 0 or 1 + or 
if ISH or MLPA showed no amplification of the HER2 gene. 
In the Netherlands, some variation in determining the HER2 
status existed in the period 2006–2016 (especially the cutoff 
for amplification (> 2,2 or ≥ 2) in the double probe ISH test). 
For this study the HER2 status as was registered in the NCR 
was used.
Compared to other authors, we did not incorporate tumor 
grade in the subtype classification [9].
If data were missing for pretreatment biopsies, this was 
substituted with data of the postoperative specimen. In all 
cases, the highest known grade was registered. Grade could 
be determined in 99% of patients who underwent a surgical 
procedure without NACT. If available, clinical lymph node 
involvement was determined on clinical and radiological 
findings and pretreatment pathological information. Patho-
logical lymph node involvement was determined after sur-
gery without NACT (pN status) or with NACT (ypN status). 
Trimodality treatment (NACT, surgery, and adjuvant locore-
gional radiation therapy) was analyzed. Chemotherapy, 
endocrine therapy, and targeted therapy (trastuzumab) were 
reported as administered or not administered. If available, 
specific types of chemotherapy were assessed. Pathological 
response to NACT was analyzed and pCR was defined as 
the absence of microscopic residual invasive cancer in the 
surgically removed specimen (ypT0 and ypTis) after NACT, 
whereas the absence of invasive residual disease in axillary 
lymph nodes was considered as lymph node pCR (ypN0). 
With respect to tumor stage, ypT1-3 tumors were considered 
to have achieved a partial response to NACT. Resection mar-
gin status was reported (from 2011 onwards) as free, focal 
incomplete, or more than focal incomplete, according to the 
Dutch Guideline for Breast Cancer Treatment. A free resec-
tion margin is defined as no tumor, either invasive and/or 
ductal carcinoma in situ (DCIS), reaching the inked margin. 
No information was available concerning re-operations.
Statistical analysis
Tumor characteristics were compared between the different 
subtypes using Chi-squared tests for categorical variables 
and non-parametric approaches (Mann–Whitney U tests) 
for continuous variables. Fisher’s exact test was used to 
determine if there were non-random associations between 
two categorical variables in case of less than five patients 
per stratum. In case of too little events to calculate the p 
value accurately, the p value was not calculated. The OS was 
calculated from the date of diagnosis to the date of death 
from any cause, or the last date of observation. Follow-up 
was calculated until time of death or end of observation. 
OS was determined using Kaplan–Meier curves and breast 
cancer subtypes were compared using the log-rank test. To 
adjust for patient-, tumor-, and treatment-related charac-
teristics, a multivariable Cox proportional hazard analysis 
was performed. Variables included were age, breast cancer 
subtype, nodal stage, histological tumor type, and grade, 
and trimodality therapy, as these variables were significantly 
different between breast cancer subtypes and significantly 
influenced the outcome (p < 0.1). For all other analyses, a p 
value < 0.05 was considered as statistically significant. All 
statistical analyses were performed in the software package 
STATA version 14.1.
Results
Patient characteristics
From 2006 to 2015, 1216 patients with stage III IBC were 
identified. After exclusion of 114 patients due to unknown 
HR/HER2 status and 41 patients with a pathological T4d 
status without clinical T4d status, 1061 patients remained 
for analysis. Clinicopathological characteristics for each 
subtype are shown in Table 1.
Histopathological and molecular characteristics
The distribution of breast cancer subtypes was as follows: 
HR+/HER2− (N = 453, 42.7%), HR−/HER2− (triple nega-
tive) (N = 258, 24.3%), HR−/HER2+ (HER2-enriched) 
(N = 180, 17.0%), HR+/HER2+ (N = 170, 16.0%). In the 
HR+/HER2− and HR+/HER2+ groups, 14 and 12 tumors, 
respectively, were ER− and PR+ .
Invasive ductal carcinoma was the most common 
type of breast cancer (85.5%) regardless of breast can-
cer subtype. Compared to the other groups, patients with 
HR−/HER2+ tumors were more likely to have a higher 
grade (p < 0.001). In 35% of patients operated following 
NACT, grade was determined pre-NACT.
Treatment of IBC
In 670 patients (63.1%), NACT was administered and least 
often in HR+/HER2− IBC. Adjuvant radiotherapy was 
220 Breast Cancer Research and Treatment (2019) 176:217–226
1 3
given in 679 patients (66.4–78.3%; 85.0% of all operated 
patients). Adjuvant radiotherapy was administered less 
often in HR+/HER2− IBC (60.9%), compared to HER2-
enriched (66.7%), HR−/HER2− (66.3%), and HR+/
HER2+ (65.9%) IBC (Table 2).
Of the 623 patients with HR-positive (HR+/HER2– and 
HR+/HER2+) IBC, 559 patients (89.7%) received anti-
hormonal treatment. In patients with HR+/HER2+ and 
HR−/HER2+ disease (350 patients), trastuzumab was 
perioperatively administered in 248 patients (70.9%).
Surgery was performed in 799 patients (75.3%), of 
which mastectomy with axillary lymph node dissection 
was performed most often in all subgroups (56.7–74.4%). 
Twenty-eight patients underwent breast-conserving ther-
apy and in 24 of these patients information concerning 
surgical margins was available: 21 patients had a complete 
and 3 patients underwent an incomplete resection.
In 560 (52.8%) of all IBC patients (and in 78.0% of 
patients who were surgically treated), trimodality therapy 
was applied, regardless of subgroups.
Pa t i e n t s  r e c e i v i n g  NAC T  we r e  yo u n ge r 
(54.0  years ± 11.8  years) compared to patients 
not receiving it  (73.7  years ± 14.6  years). The 
median age for HER2+ patients receiving trastu-
zumab was 54.6  years ± 13.7  years, compared with 
63.7 years ± 16.1 years for patients not receiving it.
Response to neoadjuvant chemotherapy
pCR of the breast tumor was achieved in 156 patients 
(23.2%), out of 670 patients who received NACT. pCR 
of the breast and lymph nodes was reported in 10 of 250 
patients with HR+/HER2− (4.0%), 24 of 116 patients 
with HR+/HER2+ (20.7%), 47 of 128 patients with 
HR−/HER2+ (36.7%), and 28 of 176 patients with 
HR−/HER2− (15.9%) (Table 3).
In patients receiving trimodality therapy, achieved pCR 
rates (after NACT and surgery and prior to adjuvant radia-
tion therapy) were HR+/HER2− 14 (6.4%), HR+/HER2+ 22 
(23.9%), HR−/HER2+ 47 (44.3%), HR−/HER2− 28 
(19.6%).
Survival outcomes
Figure 1 shows crude OS of all included patients, subdi-
vided by subtype. The study cohort had a median survival 
of 4.2 years with a median follow-up of 2.4 years (inter-
quartile range 1.1–4.5) and a 5-year OS rate of 55.6%. OS 
differed significantly between the subtypes (p < 0.001), with 
the worst OS for triple-negative IBC: HR+/HER2− (60.0%), 
H R + / H E R 2 +  ( 6 7 . 7 % ) ,  H R − / H E R 2 +  ( 5 7 . 2 % ) , 
HR−/HER2− (38.8%). After correction for confound-
ing variables, HR−/HER2− disease still was associated 
Table 1  Clinicopathological 
characteristics of all stage III 
IBC patients from 2006–2015, 
by breast cancer subtype
cN-stage clinical lymph node stage, NFS not further specified, HR hormone receptor, HER2 Human Epi-
dermal growth factor Receptor-2, SD standard deviation
$ At time of pathological analysis after surgical removal of the tumor
HR+/HER2−
(N = 453)
HR+/HER2+
(N = 170)
HR−/HER2+
(N = 180)
HR−/HER2−
(N = 258)
p value
Clinicopathological characteristics
Mean age (SD) 63.2 (16.1) 58.4 (16.2) 60.0 (16.4) 60.7 (15.3) 0.004
Histological subtype
 Ductal 362 (80.0) 152 (89.4) 168 (93.3) 225 (87.2) < 0.001
 Lobular 64 (14.1) 8 (4.7) 4 (2.2) 14 (5.4)
 Other 27 (6.0) 10 (5.9) 8 (4.4) 19 (7.4)
Grade
 1–2 109 (24.0) 20 (11.8) 12 (6.7) 18 (7.0) < 0.001
 3 59 (13.0) 26 (15.3) 46 (25.6) 97 (37.6)
 Unknown 285 (63.0) 124 (72.9) 122 (67.8) 143 (55.4)
cN-stage
 Node negative 61 (13.5) 43 (25.3) 60 (33.3) 60 (23.3) < 0.001
 Node positive 308 (68.0) 100 (58.8) 104 (57.8) 174 (67.4)
 Unknown 84 (18.5) 27 (15.9) 16 (8.9) 24 (9.3)
Resection margin  status$
 Free 169 (90.8) 89 (97.8) 95 (97.9) 108 (92.3) 0.071
 Focally incomplete 10 (5.4) 0 (0.0) 1 (1.0) 3 (2.6)
 More than focal incomplete 7 (3.8) 2 (2.2) 1 (1.0) 6 (5.1)
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with a significantly lower 5-year OS, compared to HR+/
HER2− disease [HR 2.40 (95% CI 1.29–4.45)] (Table 4).
Overall, patients who received NACT had better OS com-
pared to those who did not: 68.2% versus 34.0% (p < 0.001).
Figure 2 displays OS of the different subtypes in case of 
pCR.
In case of a combined pCR (ypT0/TisN0), an improved 
survival was observed for all subtypes, but especially for 
HER2+ tumor subtypes: HR+/HER2− (80.0 vs. 70.6%), 
HR+/HER2+ (91.7 vs. 72.4%), HR−/HER2+ (83.0 vs. 
50.0%), HR−/HER2− (57.1 vs. 42.5%) (Table 4).
A total of 68 patients underwent NACT and (any type 
of) surgery without subsequent radiotherapy.
Patients receiving subsequent radiotherapy displayed an 
improved 5-year OS as opposed to patients not receiving 
radiotherapy: 69.6 versus 55.9% (p = 0.021).
Table 2  Treatment 
characteristics of all stage III 
IBC patients from 2006–2015, 
by breast cancer subtype
BCT breast-conserving therapy, MAST mastectomy, ALND axillary lymph node dissection, NFS not further 
specified, HR hormone receptor, HER2 Human Epidermal growth factor Receptor-2
Treatment characteristics
Surgical procedure 318 (70.2) 135 (79.4) 146 (81.1) 200 (77.5)
Type of surgery
 BCT − ALND 6 (1.3) 4 (2.4) 1 (0.6) 1 (0.4) 0.086
 BCT + ALND 7 (1.6) 3 (1.8) 2 (1.1) 4 (1.6)
 MAST − ALND 46 (10.2) 26 (15.3) 8 (4.4) 23 (8.9)
 MAST + ALND 257 (56.7) 101 (59.4) 134 (74.4) 170 (65.9)
 Surgery, NFS 1 (0.2) 0 (0.0) 1 (0.6) 2 (0.8)
 ALND only 1 (0.2) 1 (0.6) 0 (0.0) 0 (0.0)
Radiotherapy
 No 152 (33.6) 49 (28.8) 48 (26.7) 56 (21.7) 0.006
 Neoadjuvant 3 (0.7) 0 (0.0) 0 (0.0) 4 (1.6)
 Adjuvant 276 (60.9) 112 (65.9) 120 (66.7) 171 (66.3)
 Radiotherapy, no surgery 22 (4.9) 9 (5.3) 12 (6.7) 27 (10.4)
Chemotherapy
 No 166 (36.6) 42 (24.7) 24 (13.3) 45 (17.4) <0.001
 Neoadjuvant 243 (53.6) 113 (66.5) 124 (68.9) 165 (64.0)
 Neoadjuvant and adjuvant 7 (1.6) 3 (1.8) 4 (2.2) 11 (4.3)
 Adjuvant 14 (3.1) 3 (1.8) 5 (2.8) 6 (2.3)
 Chemotherapy, no surgery 23 (5.1) 9 (5.3) 23 (12.8) 31 (12.2)
Type of chemotherapy
 Anthracyclines 16 (5.6) 2 (1.5) 6 (3.8) 14 (6.7) <0.001
 Taxanes 67 (23.4) 55 (43.0) 60 (38.5) 58 (27.2)
 Anthracyclines + taxanes 131 (45.6) 43 (33.6) 29 (18.6) 90 (42.2)
 NFS 67 (25.4) 28 (21.9) 61 (39.1) 51 (23.9)
Endocrine therapy
 No 42 (9.3) 22 (12.9) 173 (96.1) 247 (95.7) <0.001
 Neoadjuvant 49 (10.8) 21 (12.3) 1 (0.6) 1 (0.4)
 Neoadjuvant and adjuvant 10 (2.2) 6 (3.5) 0 (0.0) 0 (0.0)
 Adjuvant 229 (50.5) 90 (52.9) 4 (2.2) 5 (1.9)
 Endocrine therapy, no surgery 123 (27.2) 31 (18.2) 2 (1.1) 5 (1.9)
Targeted therapy
 No 448 (98.9) 41 (24.1) 31 (17.2) 255 (98.8) <0.001
 Neoadjuvant 2 (0.4) 64 (37.6) 76 (42.2) 3 (1.2)
 Neoadjuvant and adjuvant 0 (0.0) 26 (15.3) 29 (16.1) 0 (0.0)
 Adjuvant 1 (0.2) 29 (17.1) 24 (13.3) 0 (0.0)
 Targeted therapy, no surgery 2 (0.4) 10 (5.9) 20 (11.1) 0 (0.0)
Trimodality therapy
 No 234 (51.7) 78 (45.9) 74 (41.1) 115 (44.6) 0.068
 Yes 219 (48.3) 92 (54.1) 106 (58.9) 143 (55.4)
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Patients who received trimodality therapy had bet-
ter OS as opposed to those who did not have it (Fig. 3a, 
b, respectively): HR+/HER2− (74.9 vs. 46.1%), HR+/
HER2+ (80.4 vs. 52.6%), HR−/HER2+ (76.4 vs. 29.7%), 
HR−/HER2− (47.6 vs. 27.8%). After correction for age, 
breast cancer subtype, morphology, tumor grade, and clini-
cal nodal status, trimodality therapy was still associated 
with improved survival [HR 0.42 (95% CI 0.29–0.59)].
Discussion
Our study, the largest to date evaluating the impact of breast 
cancer subtypes on survival of stage III IBC, demonstrated 
that there is an important association between HR/HER2-
based subtypes and response to NACT and OS. Patients with 
triple-negative IBC have a worse survival, compared to the 
other subtypes. These results are consistent with previous 
studies [20], showing that triple-negative tumors have the 
worst prognosis despite optimal treatment. A recent popula-
tion-based study demonstrated that triple-negative and HR+/
HER2− subtypes are predictors for worse OS in IBC [9]. We 
confirmed this with respect to triple-negative tumors, but 
not for HR+/HER2− tumors. This might be due to the fact 
that in our population endocrine therapy was far more often 
administered in HR+ patients, in contrast to a US-based 
population [9].
IBC patients who responded with a pCR after NACT 
experienced an improved survival compared to non-pCR 
patients. This improved survival was observed for all 
subtypes, but especially for HER2+ tumor subtypes. In 
the present study, the pCR rates in all IBC patients were 
considerably higher (23.2%) than previously reported in 
population-based analyses [9, 21]. The HR+/HER2+ and 
HR−/HER2+ subtypes displayed the highest pCR rates. 
Likely this reflects the use of HER2-targeted therapies, 
which was more often applied in our study than in previous 
studies in case of HER2-positive disease [9, 21].
Our results were comparable with breast cancer in gen-
eral in which HR−/HER2+ achieved pCR significantly more 
often than the other subtypes and in which the prognostic 
Table 3  Pathologic response 
to neoadjuvant chemotherapy 
for the primary breast tumor 
and axillary lymph node 
status in patients with stage 
III IBC receiving neoadjuvant 
chemotherapy
cT4d ypT0 ypTis ypT1-3 ypT4 Unknown
Tumor stage response
 HR+/HER2− 250 24 (9.6) 2 (0.8) 159 (63.6) 37 (14.8)  28 (11.2)
 HR+/HER2+ 116 33 (28.5) 2 (1.7)  62 (53.4) 7 (6.0) 12 (10.3)
 HR−/HER2+ 128 55 (43.0) 14 (10.9) 41 (32.0) 8 (6.3) 10 (7.8)
 HR−/HER2− 176 44 (25.0) 4 (2.3) 90 (51.1) 25 (14.2) 13 (7.4)
 Total 670 156 (23.2) 22 (3.2) 352 (52.5) 77 (11.5) 63 (9.4)
Nodal stage response cN+ ypN0 ypN1-3 Unknown
 HR+/HER2− 192 (35.0) 23 (12.0) 165 (85.9) 4 (2.1)
 HR+/HER2+ 96 (17.5) 40 (41.7) 45 (46.9) 11 (11.5)
 HR−/HER2+ 108 (19.7) 60 (55.6) 46 (42.6)  2 (1.9)
 HR−/HER2− 152 (27.7) 43 (28.3) 102 (67.1) 7 (4.6)
 Total 548 166 (30.3) 358 (65.3) 24 (4.4)
Combined response ypT0/TisN0
 HR+/HER2− 10 (4.0)
 HR+/HER2+ 24 (20.7)
 HR−/HER2+ 47 (36.7)
 HR−/HER2− 28 (15.9)
 Total 109 (100.0)
Fig. 1  Survival curves for stage III IBC per breast cancer subtype, 
diagnosed from 2006–2015. Abbreviations: HR, hormone receptor; 
HER2, Human Epidermal growth factor Receptor-2
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impact of pCR was shown to be highest in HER2-positive 
(non-luminal) and triple-negative tumors [22].
Furthermore, similar pCR rates were found in IBC and 
NI-LABC, but IBC displayed a lower 5-year OS. These 
findings suggest that the poor prognosis in IBC might be 
the result of a higher metastatic risk and other biological 
features negatively influencing OS [23].
Although previous studies have confirmed the presence 
of the same subtypes in IBC as originally described in non-
IBC, differences do exist: approximately one-third of IBC 
is HER2+, which is notably higher than non-T4 breast can-
cer and NI-LABC [3]. Overexpression of HER2 in breast 
cancer in general is associated with higher recurrence rates 
and higher mortality, at least in the pre-trastuzumab era [7].
Despite several similarities, the present study has sev-
eral strengths not found in previous studies concerning IBC. 
First of all, this study was based on a nationwide population-
based cancer registry including unselected and unbiased data 
of all hospitals (both academic and non-academic) in the 
Netherlands, compared to mostly single-center studies [14, 
24]. Another strength is the inclusion of a very large num-
ber of patients, with twice as many patients compared to 
the largest previously published study [9]. It contains data 
of very recently treated patients with the incorporation of 
breast cancer subtypes. This has not been described in many 
of the previous studies. Furthermore, it also contains data 
of patients treated with current systemic treatments (includ-
ing trastuzumab and endocrine treatment) and we have ana-
lyzed the influence of trimodality therapy on survival. These 
issues make the results of our study highly relevant for cur-
rent daily clinical practice.
However, several limitations of our study have to be dis-
cussed. Firstly, the NCR does not register cause of death, and 
therefore breast cancer-specific survival could not be deter-
mined. Secondly, not all patients received surgery, NACT, 
adjuvant radiotherapy, and/or endocrine treatment in case of 
HR positivity. While some patients may have refused surgery 
or treatment was attenuated due to age/comorbidity, it also 
raises unanswered questions. Decisions concerning treat-
ment strategies and, more importantly, reasons for the waiver 
of (neo) adjuvant modalities could not be investigated in 
this database. Treatment recommendations are influenced by 
the experience of the treating physician and judgment about 
perceived benefit of the treatment related to the patients’ 
Table 4  Adjusted hazard ratios 
for 5-year overall survival in 
IBC patients according to breast 
cancer subtype and OS rates of 
HR/HER2 defined subtypes in 
patients with or without pCR 
following neoadjuvant therapy
a Variables included in the final multivariable model were age, breast cancer subtype, nodal stage, histo-
logical tumor type, tumor grade, trimodality therapy, pathologic complete response, and partial response to 
neoadjuvant systemic therapy. Abbreviations: OS, overall survival; HR, hormone receptor; CI, confidence 
interval; HER2, human epidermal growth factor receptor 2
Subtype Hazard ratio (95% CI)a p value
Adjusted hazard ratios for 5-year OS
 HR+/HER2− 1 (reference)
 HR+/HER2+ 1.55 (0.71–3.40) 0.266
 HR−/HER2+ 1.70 (0.75–3.85) 0.202
 HR−/HER2− 2.40 (1.29–4.45) 0.006
pCR Non-pCR
5-year OS rates (%) of different HR/
HER2-defined subtypes in case of pCR of 
non-pCR
 HR+/HER2− 80.0 70.6
 HR+/HER2+ 91.7 72.4
 HR−/HER2+ 83.0 50.0
 HR−/HER2− 57.1 42.5
Fig. 2  Survival curves for stage III IBC (diagnosed in 2006–2015) 
per molecular subtype, with clinical positive axillary lymph nodes 
who reached ypT0/TisN0 after neoadjuvant chemotherapy. Abbrevia-
tions: HR, hormone receptor; HER2, Human Epidermal growth factor 
Receptor-2
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general condition. Unfortunately, comorbidity was not reg-
istered in the NCR. Therefore, we were not able to eliminate 
it as a potential confounder. We could only account for age: 
patients receiving NACT were evidently younger compared 
to patients who did not receive it. This was also seen in the 
use of trastuzumab: the median age for patients receiving 
trastuzumab was (54.6 years ± 13.7 years), compared with 
(63.7 years ± 16.1 years) for patients not receiving it.
Unfortunately, data on risk factors associated with this 
disease are limited. The NCR does not register ethnicity, 
BMI, and maternal age at first birth [25, 26].
Furthermore, Ki-67 and tumor grade might be used in 
the classification of breast cancer subtypes [6, 27]. Com-
pared to non-inflammatory locally advanced breast can-
cer (NI-LABC), IBC has higher levels of Ki-67, which is 
associated with worse prognosis [28]. Ki-67 is not reg-
istered in the NCR, as it is not routinely assessed in the 
Netherlands. Moreover, tumor grade was unknown in 65% 
of patients who underwent NACT. Therefore, assessment 
of actual tumor grade in relation to treatment effect is dif-
ficult. Furthermore, the absence of grade might influence 
the classification in the afore mentioned tumor subtypes, 
since high-grade HR+/HER2− tumors can be regarded as 
luminal B subtypes (59 patients with high-grade HER+/
HER2− tumors were classified in the luminal A group but 
could also be included in the luminal B subtype, Table 1) 
[29]. However, grade was not included in other, but simi-
lar, population-based analyses, rendering results compa-
rable [9].
Unfortunately, information on recurrences was not avail-
able for analysis.
Our results suggest that stratification based on breast can-
cer subtypes in IBC is of clinical use for estimating the rate 
of pathological response to NACT and OS. This might aid 
in clinical decision making and counseling patients about 
anticipated outcomes. However, patients with breast can-
cer may experience changes in HR/HER2 status and tumor 
phenotype after NACT. Loss of HR positivity and the switch 
to the triple-negative phenotype after NACT also are asso-
ciated with a worse patient outcome [30]. This could not 
be analyzed because these data were unavailable in the 
database. Furthermore, a central pathology review during 
treatment was not conducted, which might have led to an 
altered receptor status based on IHC in several patients with 
subsequent changes in systemic treatment [31]. Therefore, 
the potential impact of inter-institutional discordance was 
not evaluated. However, our current analysis reflects daily 
practice in which local laboratories do not send all samples 
to a central laboratory.
The current management of stage III IBC consists of tri-
modality therapy and underutilization of trimodality therapy 
negatively impacts survival in IBC [4, 32]. We also con-
firmed the positive effect of trimodality therapy on survival. 
Remarkably, in only 78.0% of patients who were surgically 
treated trimodality therapy was applied.
Although survival in IBC patients has improved during 
the last decades, the still dismal prognosis mandates further 
improvement [3]. It is essential that eligible patients with 
non-metastatic IBC receive trimodality therapy, since this 
currently is the most effective regimen. IBC is a heteroge-
neous disease in which clinical decision making is based 
on predicting harms and benefits based on both patient and 
tumor characteristics. Recently, the concept of personal-
ized medicine has taken a more central position in cancer 
care and advances in technology (e.g., gene sequencing) 
will allow us to tailor therapies based on this knowledge. 
Future trials to evaluate molecularly targeted biological 
agents are necessary to improve survival for patients with 
this aggressive form of breast cancer. Treatment of IBC will 
be increasingly based on molecular profiling of tumors, as is 
the case in all breast cancers, rather than on histology alone. 
Fig. 3  a, b. Survival curves for stage III IBC (diagnosed in 2006–
2015), comparing patients treated with trimodality therapy (a), com-
pared to patients with T4d-breast cancer who did not receive trimo-
dality therapy (a). Abbreviations: HR, hormone receptor; HER2, 
Human Epidermal growth factor Receptor-2
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Prognostic and predictive biomarkers are eagerly awaited, 
especially for triple-negative tumors.
Conclusion
We showed that, in stage III IBC, HR/HER2-based breast 
cancer subtypes are important prognostic factors of OS and 
response to NACT. Patients with triple-negative IBC have 
the worst prognosis, despite administration of trimodality 
treatment and reached pCR.
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